Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Sep 14, 2020
After a Week of Selling, Winning and Losing Industries Emerge

After a Week of Selling, Winning and Losing Industries Emerge

Since the low in March, the overall market has gone through two pretty distinct rallies with brief interruptions in June and now again at the beginning of September. Using the S&P 500 as a barometer for the overall market, we see that the index was up 44.5% from March 23 through June 8. From June 8 through June 26, the index fell 7%. It’s hard to call a 7% decline a pullback, but the period on the chart looks more like a short-term disruption.

The second rally took place from June 26 through September 2 and it saw the index gain 19%. From September 2 through September 10, the index fell 6.75%. It isn’t clear just yet whether the current disruption in the rally is over yet or if it is the start of something bigger.

It’s unclear whether the current disruption will last longer or become something more. But I wanted to find out which sectors and industries have performed the best during the rallies and during the disruptions.

I started with the current disruption and went to Tickeron’s Group Trends Screener to find out which groups have been performing the best and the worst over the last week. On the positive side, four of the top five groups are in the healthcare sector. The Orphan group was the top performer and it refers to rare diseases, and companies in this category are biotech entities developing treatments for those diseases. The other healthcare oriented groups are Central Nervous System, Immunotherapy, and Novel Medical. All of the groups gained 4% or more as the overall market fell.

As for the downside, all 10 of the worst performing groups were associated with the oil and gas industries—the energy sector. Everything from shale, offshore drilling, oil field services were on the list of worst performers. The losses ranged from 8.36% to 11.75%.  

After looking at the performances from the different groups over the past week, I went back to look at how the different sectors performed during the different phases. I broke them down in the table below with the performances in the first rally, the first consolidation, and then the second rally. The energy sector was far and away the top performer as it rebounded from the temporary negative oil prices and the sector almost doubled from March 23 through June 8.

I used the Energy Select Sector SPDR (XLE) to represent the overall sector. Since June 8, the energy sector has fallen 29.6% and that is by far the worst performance of the bunch. We see the sector also took the worst hit during the first consolidation.

The tech sector, as represented by the Technology Select Sector SPDR (XLK), held up the best during the first consolidation and it was the top performer during the second rally with a gain of 25.1%. So far, in the current pullback, the tech sector has been the worst performer and is down over 10%.

To summarize what has happened so far, the top performing sector in the first rally became the worst performer in the first disruption. The top performer during the first disruption continued on to be the top performing sector in the second rally. Now it has been the worst performer in the second disruption. This presents an interesting dilemma and it has me wondering what the results will be once this disruption is over.

So far during the current disruption, the two sectors that have held up the best are materials and utilities. Will one of those two sectors be the top performer when the next rally happens? It is worth keeping an eye on.

Related Ticker: XLE

Contributor

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.


Momentum Indicator for XLE turns positive, indicating new upward trend

XLE saw its Momentum Indicator move above the 0 level on October 05, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 86 similar instances where the indicator turned positive. In 78 of the 86 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 59 cases where XLE's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.

XLE moved above its 50-day moving average on October 01, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +1.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where XLE advanced for three days, in 358 of 392 cases, the price rose further within the following month. The odds of a continued upward trend are 90%.

XLE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 304 of 338 cases where XLE Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Bearish Trend Analysis

The 10-day RSI Indicator for XLE moved out of overbought territory on September 03, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 46 similar instances where the indicator moved out of overbought territory. In 38 of the 46 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.

The Moving Average Convergence Divergence Histogram (MACD) for XLE turned negative on September 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 43 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 84%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XLE declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.

Notable companies

The most notable companies in this group are ExxonMobil Holdings Corporation (NYSE:XOM), Chevron Corp (NYSE:CVX), ConocoPhillips (NYSE:COP), Valero Energy Corp (NYSE:VLO), MARATHON PETROLEUM Corp (NYSE:MPC), Phillips 66 (NYSE:PSX), SLB Limited (NYSE:SLB), EOG Resources (NYSE:EOG), Kinder Morgan (NYSE:KMI), Targa Resources Corp (NYSE:TRGP).

Industry description

The investment seeks to provide investment results that, before expenses, correspond generally to the price and yield performance of publicly traded equity securities of companies in the Energy Select Sector Index. In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as Energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.

Market Cap

The average market capitalization across the State Street Energy Select Sector SPDR ETF (XLE) ETF is 115.65B. The market cap for tickers in the group ranges from 14.83B to 668.27B. XOM holds the highest valuation in this group at 668.27B. The lowest valued company is APA at 14.83B.

High and low price notable news

The average weekly price growth across all stocks in the State Street Energy Select Sector SPDR ETF (XLE) ETF was 11%. For the same ETF, the average monthly price growth was 14%, and the average quarterly price growth was 96%. MPC experienced the highest price growth at 11%, while SLB experienced the biggest fall at -2%.

Volume

The average weekly volume growth across all stocks in the State Street Energy Select Sector SPDR ETF (XLE) ETF was -16%. For the same stocks of the ETF, the average monthly volume growth was 0% and the average quarterly volume growth was -58%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 45
Price Growth Rating: 44
SMR Rating: 50
Profit Risk Rating: 27
Seasonality Score: 39 (-100 ... +100)
View a ticker or compare two or three
XLE
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

Category Energy

Category
Equity Energy
Address
One Lincoln Street Cph0326Boston
Phone
N/A
Web
www.spdrs.com
Interact to see
Advertisement
UBXG stock surged +79% over the last 30 days, driven by heightened trading volume and positive market sentiment amid broader technology sector trends. Over the past quarter, the stock rose +61%, reflecting recovery from earlier lows near its 52-week bottom.
CVGI stock surged approximately +89% over the last 30 days, driven by strong Q4 2025 earnings beat on revenue and positive 2026 guidance. Over the past quarter, shares rose about +126%, reflecting improved profitability, debt reduction, and a key partnership announcement.
SAFX stock surged +104% over the past 30 days, driven by positive updates on a $10 million capital raise and merger progress. Over the past quarter, the stock rose +44%, reflecting recovery from lows amid renewable energy sector interest and strategic developments.
LONA stock surged +80% over the past 30 days, driven by positive analyst upgrades, executive appointments, and full-year financial updates highlighting pipeline progress. Over the past quarter, shares rose +48%, reflecting improved investor sentiment in biotech amid clinical advancements.
Lifetime Brands (LCUT) stock surged +77% over the last 30 days, driven by a strong Q4 earnings beat and a Zacks Rank #1 (Strong Buy) upgrade that reflects an improved earnings outlook. Over the past quarter, shares rose +48%, supported by profitability gains despite softer sales, with adjusted EBITDA reaching $50.8 million for full-year 2025.
CURV stock surged approximately +73% over the last 30 days, driven primarily by a positive reaction to Q4 and fiscal 2025 earnings that beat expectations on EPS and revenue. Over the past quarter, the stock is up around +55%, reflecting recovery from lows near $1 amid ongoing store optimization and sub-brand launches
Blaize Holdings, Inc. (BZAI) focuses on artificial intelligence (AI)-enabled edge computing solutions, offering programmable AI processors and platforms for verticals such as smart cities, defense, retail, and enterprise markets. The company's core revolves around hardware like the Graph Streaming Processor (GSP) AI accelerator, compute cards, and software tools including Blaize AI Studio—a no-code/low-code environment for deploying AI models without source code expertise. Based in El Dorado Hills, California, and founded in 2010, it went public through a merger in early 2025.
Comstock Holding Companies, Inc. (CHCI) operates as an asset manager, developer, and operator of mixed-use and transit-oriented properties, mainly in the greater Washington, D.C. metropolitan area. The company targets high-growth urban and suburban markets, overseeing a portfolio that spans residential, commercial, hospitality, and parking assets near key metro stations. Its asset-light, fee-based model delivers recurring revenue through property management, leasing, development services, and asset recapitalization for institutional investors, family offices, and governments.
ARM stock surged +26% over the past 30 days, driven by announcements of in-house chip production and strong analyst upgrades amid AI enthusiasm. Over the past quarter, the stock climbed +38%, reflecting robust Q3 earnings beat with 26% revenue growth and data center royalty doubling.
Sable Offshore Corp. (SOC) is an independent oil and gas company focused on offshore operations in federal waters off California. The company owns and operates three platforms in the Santa Ynez Unit (SYU), spanning 16 federal leases across approximately 76,000 acres, along with subsea pipelines for crude oil, natural gas, and produced water transport to onshore facilities. Its core business model centers on restarting and developing prolific fields like the SYU, which had been idle due to regulatory and legal hurdles following a 2015 pipeline spill.
From what I see, Cheniere Energy Partners (CQP) holds a commanding position through its ownership and operation of the Sabine Pass LNG terminal in Louisiana, the largest LNG production facility in the U.S. with approximately 30 million tonnes per annum (mtpa) capacity across six trains, alongside the connected Creole Trail Pipeline. This setup makes CQP a leader in U.S. LNG exports, which have accounted for about 11% of global supply in recent years. The company's ~80% contracted production through long-term sale and purchase agreements (SPAs) provides revenue stability, with weighted average remaining lives of around 13 years.
In my view, Regeneron Pharmaceuticals holds a strong leadership position in biotechnology, thanks to its proprietary VelociSuite technologies, including VelocImmune for fully human antibody discovery. This enables a robust pipeline across immunology, oncology, ophthalmology, and rare diseases. The company's integrated model—from discovery to commercialization—drives high R&D productivity, with approximately 45 clinical programs and key partnerships like Sanofi for Dupixent and Bayer for EYLEA.
As I review argenx SE's place in the market, its strong footing in immunology stands out. This commercial-stage biopharmaceutical company focuses on differentiated antibody therapies for severe autoimmune diseases. The flagship product, VYVGART (efgartigimod), a first-in-class neonatal Fc receptor (FcRn) inhibitor, has secured leadership in generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP), with approvals across the U.S., Europe, and Japan. The Immunology Innovation Program (IIP) fuels a robust pipeline, featuring next-generation FcRn candidates like ARGX-213 and ARGX-124, alongside first-in-class assets such as empasiprubart (C2 inhibitor, ARGX-117) and adimanebart (MuSK agonist).
I've long admired Alnylam Pharmaceuticals as the pioneer in RNA interference (RNAi) therapeutics, a gene-silencing technology that has delivered six approved products, including AMVUTTRA (vutrisiran), ONPATTRO (patisiran), GIVLAARI (givosiran), and OXLUMO (lumasiran). The company's proprietary platform, enhanced by GalNAc conjugation for liver targeting and emerging extra-hepatic delivery innovations, creates a solid competitive moat in precision genetic medicines.
As I review BeOne Medicines AG's position in the oncology space, what stands out is its role as a global leader with a diversified portfolio that includes both commercial-stage therapies and a deep pipeline targeting hematologic and solid tumors. The flagship product, BRUKINSA (zanubrutinib), a Bruton's Tyrosine Kinase (BTK) inhibitor, has secured approvals in over 75 markets, solidifying its dominance in chronic lymphocytic leukemia (CLL) and other blood cancers. This is complemented by TEVIMBRA (tislelizumab), an anti-PD-1 antibody approved in more than 50 markets for various indications, which broadens its reach in immunotherapy.
Rio Tinto holds a premier position as one of the world's largest mining companies, anchored by low-cost, Tier 1 assets. Its Pilbara iron ore operations in Australia deliver industry-leading margins, thanks to integrated rail and port infrastructure that gives it a structural cost advantage over higher-cost producers. In copper, the company has significant stakes in Escondida, the world's largest copper mine, and full ownership of Oyu Tolgoi in Mongolia, setting it up well to benefit from tightening supply as demand surges for electrification and renewables.
I've always been impressed by how Visa (V) commands the global payments landscape. As an open-loop network, it connects issuers, acquirers, merchants, and consumers without issuing cards or extending credit itself. The VisaNet platform processes over 65,000 transactions per second across more than 200 countries, supporting a ~52% share of the global credit card market and ~60% of debit. This scale generates powerful network effects, where greater adoption benefits everyone involved and creates formidable barriers to entry.
Following the Kenvue consumer health spin-off, Johnson & Johnson has transformed into a focused healthcare leader, emphasizing Innovative Medicine (pharmaceuticals) and MedTech (devices). In my view, this repositioning sharpens the company's edge in high-margin areas such as oncology, immunology, neuroscience, cardiovascular, surgery, and vision, where its diversified portfolio and R&D efficiency provide clear competitive advantages.
I've long appreciated ASML Holding N.V.'s dominant position in the semiconductor lithography market. The company commands over 90% share in advanced deep ultraviolet (DUV) immersion systems and 100% in EUV lithography—the critical technology for chips below 7nm nodes used in AI, high-performance computing, and memory. This near-monopoly comes from decades of R&D investment, exclusive partnerships like Zeiss for optics, and a vast installed base that generates steady service revenue. From what I see, competitors such as Nikon and Canon remain far behind in EUV, sticking to mature nodes.
I've been watching Micron Technology (MU) closely through its recent volatility, which mirrors the semiconductor sector's heightened sensitivity to AI demand and supply constraints. The stock saw a sharp post-earnings sell-off tied to elevated capital expenditure plans, yet it has rebounded with surging DRAM prices—up 90-95%—and memory suppliers booked out for years. From what I see, broader tech optimism, including key partnerships and persistent supply tightness, is driving upward momentum. This positions MU as a pivotal player in high-bandwidth memory (HBM) for data centers. Trading near recent highs around $368, the shares highlight investor focus on Micron's critical role in the AI infrastructure expansion under these constrained industry conditions.
After a Week of Selling, Winning and Losing Industries Emerge